Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma

被引：0
|
作者：
Di-Han Liu
Ze-Rui Zhao
Yao-Bin Lin
Wen-Jie Zhou
Jing-Yu Hou
Zheng-Hao Ye
Hao Long
机构：
[1] Collaborative Innovation Center for Cancer Medicine,Department of Thoracic Surgery, State Key Laboratory of Oncology in Southern China
[2] Sun Yat-Sen University Cancer Center,undefined
[3] Lung Cancer Research Center,undefined
[4] Sun Yat-Sen University,undefined
来源：
Annals of Surgical Oncology | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1934 / 1941
页数：7
相关论文
共 50 条
  • [1] Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma
    Liu, Di-Han
    Zhao, Ze-Rui
    Lin, Yao-Bin
    Zhou, Wen-Jie
    Hou, Jing-Yu
    Ye, Zheng-Hao
    Long, Hao
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (06) : 1934 - 1941
  • [2] ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma
    Long, Hao
    Liu, Di-Han
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S853 - S854
  • [3] ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma
    Hao Long
    Di-Han Liu
    [J]. Annals of Surgical Oncology, 2019, 26 : 853 - 854
  • [4] Epidermal Growth Factor Receptor-mutated Lung Cancer as the Initial Manifestation of Germline TP53 Mutation Associated Cancer
    Pathak, Surabhi
    Singh, Sunny R. K.
    Katiyar, Vatsala
    Mcdunn, Susan
    [J]. CUREUS, 2018, 10 (03):
  • [5] CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma
    Hasegawa, Mizue
    Sakai, Fumikazu
    Ishikawa, Rinako
    Kimura, Fumiko
    Ishida, Hironori
    Kobayashi, Kunihiko
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 819 - 826
  • [6] A Meta-Analysis and Bioinformatics Exploration of the Prognostic Value of TP53 Co-Mutations in EGFR Mutated NSCLC
    Jiang, R.
    Wang, F.
    Li, S.
    Wang, X.
    Wang, L.
    Huang, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S670 - S670
  • [7] TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
    Ruofei, Yu
    Hua, Bai
    Tangai, Li
    Bingyu, Gao
    Jiefei, Han
    Geyun, Chang
    Pei, Zhang
    Kailun, Fei
    Xiran, He
    Jie, Wang
    [J]. TRANSLATIONAL ONCOLOGY, 2021, 14 (09):
  • [8] A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD)
    Zhu, Ying
    Guo, Yu-Biao
    Xu, Di
    Zhang, Jing
    Liu, Zhen-Guo
    Wu, Xi
    Yang, Xiao-Yu
    Chang, Dan-Dan
    Xu, Min
    Yan, Jing
    Ke, Zun-Fu
    Feng, Shi-Ting
    Liu, Yang-Li
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (07)
  • [9] Stability of rare TP53 co-mutations in AML patients.
    Bloom, Kenneth Joel
    Idica, Adam
    Smart, Dave
    Allen, Wendy
    Scanlon, Enya
    Clark, Jordan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] The role of PTEN and TP53 co-mutations in immunotherapy of lung cancer.
    Ma, Xiaolong
    Zhang, Ding
    Chen, Shiqing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345